

Figure 4. Hypoxia-induced TSSs for putatively non-protein-coding RNAs. (A) Genomic positions of the regions in which activated TSSs highly concentrated (red circle). Number of RefSeq genes overlapping the corresponding 100 kb region is shown in the left margin. Examples of regions in which large numbers of transcription initiation sites were induced by hypoxia even in intergenic regions [(B): a 100 kb region in Chromosome 8] and inside genic regions [(C): a 100 kb region in Chromosome 17]. The vertical axis represents fold induction of the TSS-tag counts. TSSs of the genic region of NM_019613 (WDR45-like protein gene) are shown in the bottom margin. The direction of the transcription of the RefSeq gene is represented by a red arrow. Radius of each circle represents the number of TSS-tags. Colour of each circle indicates the direction of the transcription (red: same direction with the RefSeq gene; blue: opposite direction of the RefSeq gene). Putative alternative promoters on which confirmation analysis by real-time RT-PCR is shown in (D) are indicated in red and blue letters (AP1-3). AP: Alternative Promoter. (D) Real-time RT-PCR analysis of the putative alternative promoters, AP1-3, shown in (C). Fold inductions calculated by TSS-tag counts and real-time RT-PCR are shown in the third and fourth column, respectively. Primer sequences are shown in Supplementary Table 10. Note that we used first strand single-strand cDNA as template, so that the PCR amplification should be strand-sensitive. (*) Also note that fold inductions estimated for AP3 by TSS-tag counts were the sum of the upstream promoters. As the AP3 were located inside of the last exon, it was impossible to design PCR primers which discriminate the transcript products of AP3 from those of other upstream promoters. Results of the independent oligo-cap RACE analysis for each of the APs are also shown in Supplementary Figure 6.

genes. For this, we used the 220 hypoxia-induced intergenic TSCs with TSS-tags of >10 ppm. We found that, in 28 cases, the nearest genes were also up-regulated by >2.5 -fold, while down-regulation by >2.5 -fold was observed only in five cases. The TSS-tag count level of the intergenic TSCs correlated with that of the nearest protein-coding genes (upper panels in Supplementary Figure 2). When other intergenic TSCs were also considered as the nearest TSCs, this correlation became even more significant. A similar tendency for co-elevation of proximal transcriptions was also observed for hypoxia-responsive TSCs which were mapped to antisense positions of RefSeq genes. Among 124 hypoxia-induced antisense TSCs with >10 ppm TSS-tags, the corresponding protein-coding transcripts were also up- and down-regulated by more than 2.5-fold in 24 cases and two cases, respectively. Again, the TSS-tag counts of putative non-coding transcripts and the corresponding antisense protein-coding transcripts were at similar levels (lower panels in Supplementary Figure 2).

Alternative hypoxia responsive promoters

Among 6366 hypoxia-induced TSCs, which were located within RefSeq genes, 441 TCS had TSS-tags >10 ppm. Among them, 191 had expression levels of particular individual alternative promoters significantly altered (>5 -fold when the individual TSCs were evaluated) while the total gene-expression levels were not changed (<5 -fold when the TSCs belonging to the corresponding genes were totalled). A list of the promoters is shown in Supplementary Table 6. Figure 5 shows a typical but biologically interesting case in which alternative promoters were employed differentially between hypoxic and normoxic conditions. In the p53 tumor suppressor gene family, usage of alternative promoters has been reported for the p73 and p63 genes. In these genes, the upstream promoters encode functional transcriptional activator (TA) proteins and the downstream promoters encode non-functional silencers (DN) (36). We observed clear differential usages of these alternative promoters. In particular, in both of the p63 and p73 genes, the upstream (TA) promoters were down-regulated by hypoxia, while the downstream (DN) promoters were up-regulated. These results were consistent with the previous report that TAp63 down-regulates and DNp63 up-regulates VEGF expression (36). We observed that TSS-tag counts of the VEGF gene were induced by 9-fold by hypoxia. In addition to its pivotal roles in regulating cell cycle and apoptosis, p53 is also reported to be involved in modulating the balance between the respiratory and glycolysis pathways by controlling the expression levels of several downstream effectors, including COX complex mitochondrial respiratory genes (37). In this study, 60% reduction of TSS-tag counts for the COX complex assembly gene, the SCO2 gene, was observed. In DLD-1 cells, we observed neither differential usage of the alternative promoters nor overall gene-expression change in the p53 gene itself. It has been reported that the protein-coding sequence of p53 is mutated and the p53 protein product is non-functional in DLD-1 cells. p63 and p73, which share a well-conserved

DNA-binding domain with p53, may complementarily regulate downstream target genes of p53. A drastic shift of the p63 and p73 usage from TA to DN supposedly contributes to adaptation of cancer cells to hypoxia.

HIF cascade in hypoxia responsive genes

There were 120 protein-coding genes whose expression levels were induced >5 -fold and >10 ppm by hypoxia. These are the putative 'hypoxia-induced genes' selected using the strict criteria (a list of the genes and their annotations are shown in Supplementary Table 7; note that some of the previously identified hypoxia induced genes are not included there because the either fold induction was below 5 or expression level was below 10 ppm). We examined whether any of the gene groups were enriched in these 'hypoxia induced genes' for particular Gene Ontology categories (38) or KEGG (39) pathways. We found that 'glycolysis' related genes were particularly enriched ($P < 0.002$ and $P < 0.0008$ for GO and KEGG categories, respectively, by calculating hypergeometric distributions). We also examined the fold induction of all of the genes belonging to this gene category. We found that distribution of the fold inductions were statistically significantly deviated compared to other gene groups (Figure 6; $P < 0.06$ and $P < 0.002$ for GO and KEGG categories, respectively, by Wilcoxon signed rank test; also see Supplementary Figure 3 and Supplementary Table 11). Interestingly, while the genes encoding enzymes which enhance glycolysis were ubiquitously up-regulated under hypoxia, only FBP, which codes for glycolysis-suppressing fructose-1,6-bisphosphatase, was strikingly down-regulated. On the other hand, genes encoding the enzymes involved in the Complex I of oxidative phosphorylation in mitochondria were down-regulated (Supplementary Figure 4). Although it is a well-known fact that the glycolysis pathway is activated in response to hypoxia, shifting metabolism from oxygen-requiring oxidative phosphorylation to oxygen-independent glycolysis to obtain ATP (40), this is the first report to quantitatively measure gene expression changes (or system-perturbation of a particular gene network) in terms of the absolute copy number for each gene component.

We then compared changes in TSS-tag counts by transfecting siRNAs targeting HIF1A and HIF2A to evaluate dependency of hypoxia-induced gene-expression levels on HIF transcription factors. Expression of both HIF1A and HIF2A was suppressed by about 70% according to the TSS-tag counts and real-time RT-PCR analysis (Supplementary Table 8; also see Supplementary Figure 7). Among the 120 hypoxia-induced genes, 15 genes were identified with mRNA levels reduced by 80% by RNAi of HIF1A. Meanwhile, HIF2A RNAi caused reduction of mRNA levels of 36 genes. We also examined the sequences of the regions proximal to their TSSs (1 kb upstream to 200 bases downstream) and found clear consensus sequences of the HIF1 and HIF2-binding sites (41) in 11 (79%) and 31 (86%) cases, respectively (a list of the genes is shown in Supplementary Table 9). Although further compilation of the experimental data is obviously essential




Figure 5. Hypoxia-induced TSCs in p53 family genes. (A) Count of TSS-tags mapped at the corresponding genomic regions. Red and blue solid bars represent the TSS-tag counts from normoxia and hypoxia, respectively. Exon-intron structures of the RefSeq transcripts are shown in the bottom margins. The genome regions depicted in the bar graphs are magnifications of the regions indicated by thin blue lines. Whether the transcripts from the corresponding promoters should encode the transcriptionally active (TA) or negative (DN) forms is shown in the margin. AP: alternative promoter. (B) Validation of the results shown in (A) by real-time RT-PCR analysis. Promoter ID is as of those represented in the bar graphs in (A). For p63, PCR primers were set in exon 3, so that TA-type transcripts are selectively amplified. Primer sequences are shown in Supplementary Table 10.

before concluding they are actually direct binding sites of the HIF1 and HIF2, they should be the first targets for exploring the transcriptional network mediated by HIF1 and HIF2.

Interestingly, all of the 15 'HIF1A-dependent' genes were also suppressed by HIF2A RNAi. On the other hand, only one-third (12 out of 36 genes) of 'HIF2A-dependent' genes were suppressed by HIF1A reduction. Under hypoxia, the total number of TSS-tags

corresponding to HIF1A was increased by 1.5-fold, and HIF2A RNAi reduced the HIF1A-expression level by 60%. Meanwhile, HIF2A expression was not significantly increased by hypoxia, and HIF1A RNAi did not reduce the HIF2A-expression level. These results suggest that HIF2A may regulate hypoxia-induced HIF1A expression. Thus, the effect of hypoxia-activated HIF2A appears to be transmitted to downstream hypoxia-responsive genes not only directly but also




Figure 6. Hypoxia-invoked response of the glycolysis gene network. Expression of glycolysis-enhancing enzymes (masked with pale pink) was up-regulated while that of glycolysis-suppressing enzymes (masked with pale blue) was down-regulated. Human genes assigned to the glycolysis pathway map of the KEGG database were selected, and TSS-tag numbers of the corresponding genes were evaluated. Red bars and blue bars represent TSS-tag ppm in normoxia and hypoxia respectively. Fold induction for each of the genes is shown in Supplementary Table 11. Genes included in the list of the 'hypoxia-induced' 120 genes are highlighted by green boxes. Note that, since we used the stricter criteria for selecting hypoxia-induced genes (>10 p.p.m., >5-fold induction), many of the genes belonging to this pathway are not directly included in the list, though they showed inductions at least to some extent.

indirectly via HIF1A in DLD-1 cells. Previous studies have assumed pivotal roles for HIF1A; while the roles of HIF2A remain mostly uncharacterized, perhaps because of its low expression level (42). The total TSS-tag number of HIF1A was about 4-fold larger

than that of HIF2A in this study. In contrast to previous estimates, the high sensitivity of our method may have revealed that the hitherto-supposed 'minor' HIF2A plays a dominant role in the hypoxia response.

Table 2. Statistics of the TSS-tags generated from other cell lines

| | Relative to RefSeq regions | | Relative to exons of RefSeq gene models | | | |
|---------------------------|----------------------------|------------------------|---|----------------|----------------|-------------|
| | #total mapped tag | #NM-associated tag (%) | Upstream (%) | First exon (%) | Other exon (%) | Intron (%) |
| MCF7 1% O ₂ | 7950745 | 7259512 (91) | 2221013 (31) | 3859864 (53) | 589298 (8) | 589337 (8) |
| MCF7 21% O ₂ | 14189873 | 12955252 (91) | 3828159 (30) | 6974356 (54) | 989360 (8) | 1163377 (9) |
| HEK293 1% O ₂ | 10886858 | 10233645 (94) | 3216794 (31) | 5764173 (56) | 786235 (8) | 466443 (5) |
| HEK293 21% O ₂ | 8303754 | 7766894 (94) | 2343996 (30) | 4516688 (58) | 593494 (8) | 312716 (4) |
| TIG3 1% O ₂ | 9043423 | 8273656 (91) | 1993830 (24) | 4977677 (60) | 799727 (10) | 502422 (6) |
| TIG3 21% O ₂ | 9501473 | 8686047 (91) | 2159571 (25) | 5300938 (61) | 657096 (8) | 568442 (7) |

As is the case in Table 1, mapped positions of the TSS-tags were counted relative to RefSeq regions and relative to exons of RefSeq gene models, when mapped inside of the RefSeq regions.

Table 3. The number of 'hypoxia responsive' genes identified from indicated cell lines; overlap with the 'hypoxia responsive' genes in DLD-1 is shown in the second line (Panel A); for the 'glycolysis pathway' genes (shown in Figure 6), average fold change (first line) and the TSS-tag counts in p.p.m. in hypoxic conditions (second line) were calculated (Panel B)

| Panel A | | | | |
|-------------------------------------|-------|----------------------|------------------------|------------------------|
| | MCF7 | HEK293 | TIG3 | |
| >5-fold induction (>10 p.p.m.) | 86 | 24 | 9 | |
| Overlap with DLD1 | 27 | 3 | 4 | |
| Panel B | | | | |
| | DLD-1 | MCF7 | HEK293 | TIG3 |
| Average fold change | 3.6 | 3.5 ($P = 0.92$) | 1.2 ($P = 7.6e-6$) | 2.0 ($P = 0.11$) |
| Average p.p.m. in 1% O ₂ | 922.9 | 657.8 ($P = 0.33$) | 209.9 ($P = 7.6e-7$) | 542.7 ($P = 3.8e-3$) |
| Panel C | | | | |
| | MCF7 | HEK293 | TIG3 | |
| 'Hot region' | 37 | 8 | 9 | |
| Overlap with DLD1 | 3 | 1 | 0 | |

Statistical significances of the difference compared with the cases in DLD-1, which were calculated by paired Wilcoxon test, are shown in the parentheses.

Hypoxia responses in different cell lines

In order to further investigate the biological relevance of the cellular responses to hypoxia observed in DLD-1, we performed similar analysis using three different cell types; MCF7, HEK293 and TIG3 cells. These cells are breast cancer epithelial cells, non-cancerous immortalized embryonic kidney epithelial cells and normal (primary) embryonic lung fibroblasts, respectively. We constructed a series of TSS-tag libraries from these cells cultured under 21% and 1% O₂. From each of the libraries, 8–15 million TSS-tags were generated. Overall qualities of the TSS-libraries were similar to those of the DLD-1 libraries (Table 2).

Using these new TSS-libraries, we examined gene-expression changes invoked by hypoxia in the different cells. The numbers of 'hypoxia responsive' genes (as is the case of the DLD-1: >5-fold induction; >10 ppm) significantly differed between the cell types (Table 3A). Eighty-six genes were 'hypoxic induced' in MCF7 cells, while far less genes were induced in HEK293 cells and TIG3 cells. Many of the hypoxia responsive genes in MCF7 cells overlapped with those in DLD-1 cells, while the overlaps in the other cell lines were very scarce. Particularly, we focused on the 'glycolysis pathway'

(Figure 6) and observed significant difference in the expression changes between the cell types in this pathway. For the genes belonging to the glycolysis pathway, gene-expression changes in HEK293 cells and TIG3 cells were smaller than in DLD-1 cells in terms of fold inductions as well as absolute gene-expression levels, while those of MCF7 cells were almost at the level of DLD-1 cells (Table 3B).

We could also identify 'hot regions' in these cell lines (Table 3C). However, the number of 'hot regions' was different between the cell types. Particularly, there were far more 'hot regions' in DLD-1 and MCF7 cells than in TIG3 and HEK293 cells. Interestingly, three of the 'hot regions' overlapped between DLD-1 cells and MCF7 cells (Supplementary Table 4A), and should thus be prioritized for further functional characterizations.

DISCUSSION

We have described a simple method to massively collect positional information of TSSs together with digital information of the expression levels of the transcripts. By this approach, time, costs and efforts necessary for laborious cDNA cloning and sequencing steps could be greatly reduced. Most part of the technical difficulties to construct

a full-length cDNA library or a 5' SAGE or CAGE library could be skipped. Although other cap selection methods, such as the cap-trapper (10) and Smart system (43), can be also applied for massively parallel sequencing systems, our oligo-capping method has a clear advantage. Among those similar methods, only oligo-capping includes a step to replace the cap structure with synthetic oligo, in which sequence necessary for massively parallel sequencing can be embedded. Therefore, the protocol presented here should be applicable for any other massive sequencing technologies.

This approach has several advantages compared to the current expression profiling methods. Compared with microarray-based or real-time PCR-based approaches, our method does not need any probes or PCR primers, which should be designed based on presumed transcript sequences, and thus prevent the detection of novel transcripts with these previous methods. Also, while the previous methods are designed to detect relative change in expression of the same transcript between two states, absolute quantification of the transcripts could be enabled only by our method. Compared with the recent RNA-Seq method (26,44,45), our method has two major advantages and one clear disadvantage. Advantages are: (i) exact positional information of the TSS can be obtained; (ii) throughput of the expression analysis is better because our method does not sequence internal part of transcripts. A disadvantage is that our method cannot detect the splicing pattern of the exons.

A series of validation analyses showed that the data from our new method is quite reliable (Figures 2 and 3). However, in some cases, we also noticed that there were some discrepancies (Figures 2B and 3A). Because we did not use redundantly mapped TSS-tags, we may have incorrectly assigned small number of TSS-tag counts, when a real TSS is located within repetitive sequence elements. Conversely, the expression level could have been overestimated, when a small population (but a large number) of TSS-tags deviated from a huge TSS cluster by sequence errors, which would be mapped elsewhere otherwise, were uniquely mapped at the corresponding gene region. Careful evaluation is crucial especially when the redundantly mapped tags would be rescued (46). In either case, confirmation analysis on individual genes should be essential, as was the case with microarray analysis in its early days.

Taking advantages of our new method, we revealed genome-wide changes of the transcriptional landscape in response to hypoxia for the first time. (All the sequence data and the cluster data will be made freely available from our web site (DBTSS: <http://dbtss.hgc.jp/>) and from NCBI Short Read Archives (<http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?>) under the accession number of SRA003625. Visualization of some of the results for each gene is also available there (for example, see Supplementary Figure 5). In our analysis, we identified 'hot regions' where hypoxia-induced promoters are enriched in particular genomic regions, as well as 'hot' genes which have many hypoxia-responsive alternative promoters. It is possible that hypoxia-invoked chromosomal changes came to allow access of transcriptional

factors in a somewhat global manner. Consistently, some of the transcriptions from proximal regions, occasionally including transcriptions of putative non-protein-coding transcripts, seemed to be under similar regulation (Supplementary Figure 3), with the extreme cases being the above-mentioned 'hot regions'. These observations could be explained if the surrounding chromosome context, which shapes the transcriptional landscape proximally, is shared between the TSCs of non-protein-coding transcripts and the TSCs of RefSeq transcripts.

It is noteworthy that some of such 'hot regions' were also identified from different cell types of distinct cancer origin, though number and frequencies of them were different. It should be important to further analyze cells of other mammalian species under hypoxia to see whether these 'hot regions' or 'hot' genes are evolutionarily conserved. Genome-wide high-throughput methods to monitor DNA binding of proteins (42), DNA and histone modifications (47,48) and DNase I hyper sensitive sites (49) or combination of them (50), will be needed for directly analyzing chromosomal structural changes.

It should be also noteworthy that the gene-expression changes were somewhat similar between DLD-1 and MCF7 cells, though they were distinct from HEK293 and TIG3 cells. Both DLD-1 and MCF7 cells were derived from solid tumour, which may have originally grown in hypoxic conditions. The enhanced gene-expression changes observed in DLD-1 and MCF7 should explain the distinct biology of the cells in response to hypoxia.

Indeed, various new types of analyses have been enabled by the hereby described method, in which detection of TSS positions and digital-expression information can be obtained without a prior knowledge of transcript structures. Although this is only the first step towards monitoring dynamic behavior of the human transcriptome, our new method and its application will supply a unique tool for thorough understanding of the dynamic nature of the transcriptional program encoded by the human genome.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We are grateful to K. Abe, E. Sekimori, K. Imamura and H. Onozuka for technical supports. We are also thankful to Dr Sierro, Dr M. Frith and Mr F. Sathirapongsasuti for critical reading of the manuscript.

FUNDING

This work was supported by grants from the Ministry of Economy, Trade and Industry (METI) of Japan, the Japan Key Technology Center project of METI of JAPAN, Grants for the Third-Term Comprehensive 10-Year Strategy for Cancer Control and Grants-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare and a Grant-in-Aid for Scientific Research on

Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology-Japan. Funding for open access charge: Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology Japan.

Conflict of interest statement. None declared.

REFERENCES

- Harris, A.L. (2002) Hypoxia—a key regulatory factor in tumour growth. *Nat. Rev. Cancer*, **2**, 38–47.
- Keith, B. and Simon, M.C. (2007) Hypoxia-inducible factors, stem cells, and cancer. *Cell*, **129**, 465–472.
- O'Reilly, S.M., Leonard, M.O., Kieran, N., Comerford, K.M., Cummins, E., Pouliot, M., Lee, S.B. and Taylor, C.T. (2006) Hypoxia induces epithelial amphiregulin gene expression in a CREB-dependent manner. *Am. J. Physiol. Cell Physiol.*, **290**, C592–C600.
- Mizukami, Y., Kohgo, Y. and Chung, D.C. (2007) Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. *Clin. Cancer Res.*, **13**, 5670–5674.
- Chi, J.T., Wang, Z., Nuyten, D.S., Rodriguez, E.H., Schaner, M.E., Salim, A., Wang, Y., Kristensen, G.B., Helland, A., Borresen-Dale, A.L. et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. *PLoS Med.*, **3**, e47.
- Wang, V., Davis, D.A., Haque, M., Huang, L.E. and Yarchoan, R. (2005) Differential gene up-regulation by hypoxia-inducible factor-1 α and hypoxia-inducible factor-2 α in HEK293T cells. *Cancer Res.*, **65**, 3299–3306.
- Elvidge, G.P., Glenn, L., Appelhoff, R.J., Ratcliffe, P.J., Ragoussis, J. and Gleade, J.M. (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1 α , HIF-2 α , and other pathways. *J. Biol. Chem.*, **281**, 15215–15226.
- Detwiller, K.Y., Fernando, N.T., Segal, N.H., Ryeom, S.W., D'Amore, P.A. and Yoon, S.S. (2005) Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. *Cancer Res.*, **65**, 5881–5889.
- Mense, S.M., Sengupta, A., Zhou, M., Lan, C., Bentsman, G., Volsky, D.J. and Zhang, L. (2006) Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. *Physiol. Genomics*, **25**, 435–449.
- Carninci, P. and Hayashizaki, Y. (1999) High-efficiency full-length cDNA cloning. *Methods Enzymol.*, **303**, 19–44.
- Suzuki, Y. and Sugano, S. (2003) Construction of a full-length enriched and a 5'-end enriched cDNA library using the oligo-capping method. *Methods Mol. Biol.*, **221**, 73–91.
- Kato, S., Ohtoko, K., Ohtake, H. and Kimura, T. (2005) Vector-capping: a simple method for preparing a high-quality full-length cDNA library. *DNA Res.*, **12**, 53–62.
- Ederly, I., Chu, L.L., Sonenberg, N. and Pelletier, J. (1995) An efficient strategy to isolate full-length cDNAs based on an mRNA cap retention procedure (CAPture). *Mol. Cell Biol.*, **15**, 3363–3371.
- Ota, T., Suzuki, Y., Nishikawa, T., Otsuki, T., Sugiyama, T., Irie, R., Wakamatsu, A., Hayashi, K., Sato, H., Nagai, K. et al. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs. *Nat. Genet.*, **36**, 40–45.
- Kimura, K., Wakamatsu, A., Suzuki, Y., Ota, T., Nishikawa, T., Yamashita, R., Yamamoto, J., Sekine, M., Tsuritani, K., Wakaguri, H. et al. (2006) Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. *Genome Res.*, **16**, 55–65.
- Wakaguri, H., Yamashita, R., Suzuki, Y., Sugano, S. and Nakai, K. (2008) DBTSS: database of transcription start sites, progress report 2008. *Nucleic Acids Res.*, **36**, D97–D101.
- Hashimoto, S., Suzuki, Y., Kasai, Y., Morohoshi, K., Yamada, T., Sese, J., Morishita, S., Sugano, S. and Matsushima, K. (2004) 5'-end SAGE for the analysis of transcriptional start sites. *Nat. Biotechnol.*, **22**, 1146–1149.
- Shiraki, T., Kondo, S., Katayama, S., Waki, K., Kasukawa, T., Kawaji, H., Kodzius, R., Watahiki, A., Nakamura, M., Arakawa, T. et al. (2003) Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. *Proc. Natl. Acad. Sci. USA*, **100**, 15776–15781.
- Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M.C., Maeda, N., Oyama, R., Ravasi, T., Lenhard, B., Wells, C. et al. (2005) The transcriptional landscape of the mammalian genome. *Science*, **309**, 1559–1563.
- Carninci, P., Sandelin, A., Lenhard, B., Katayama, S., Shimokawa, K., Ponjavic, J., Semple, C.A., Taylor, M.S., Engstrom, P.G., Frith, M.C. et al. (2006) Genome-wide analysis of mammalian promoter architecture and evolution. *Nat. Genet.*, **38**, 626–635.
- Landry, J.R., Mager, D.L. and Wilhelm, B.T. (2003) Complex controls: the role of alternative promoters in mammalian genomes. *Trends Genet.*, **19**, 640–648.
- Davuluri, R.V., Suzuki, Y., Sugano, S., Plass, C. and Huang, T.H. (2008) The functional consequences of alternative promoter use in mammalian genomes. *Trends Genet.*, **24**, 167–177.
- Bentley, D.R. (2006) Whole-genome re-sequencing. *Curr. Opin. Genet. Dev.*, **16**, 545–552.
- Okazaki, Y., Furuno, M., Kasukawa, T., Adachi, J., Bono, H., Kondo, S., Nikaido, I., Osato, N., Saito, R., Suzuki, H. et al. (2002) Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. *Nature*, **420**, 563–573.
- Willingham, A.T. and Gingeras, T.R. (2006) TUF love for “junk” DNA. *Cell*, **125**, 1215–1220.
- Sultan, M., Schulz, M.H., Richard, H., Magen, A., Klingenhoff, A., Scherf, M., Seifert, M., Borodina, T., Soldatov, A., Parkhomchuk, D. et al. (2008) A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. *Science*, **321**, 956–960.
- Sakakibara, Y., Irie, T., Suzuki, Y., Yamashita, R., Wakaguri, H., Kanai, A., Chiba, J., Takagi, T., Mizushima-Sugano, J., Hashimoto, S. et al. (2007) Intrinsic promoter activities of primary DNA sequences in the human genome. *DNA Res.*, **14**, 71–77.
- Barrett, T., Troup, D.B., Wilhite, S.E., Ledoux, P., Rudnev, D., Evangelista, C., Kim, J.F., Soboleva, A., Tomashevsky, M. and Edgar, R. (2007) NCBI GEO: mining tens of millions of expression profiles – database and tools update. *Nucleic Acids Res.*, **35**, D760–D765.
- Blasco, M.A. (2007) The epigenetic regulation of mammalian telomeres. *Nat. Rev. Genet.*, **8**, 299–309.
- Mattick, J.S. and Makunin, I.V. (2006) Non-coding RNA. *Hum. Mol. Genet.*, **15** Suppl 1, R17–R29.
- Griffiths-Jones, S., Saini, H.K., van Dongen, S. and Enright, A.J. (2008) miRBase: tools for microRNA genomics. *Nucleic Acids Res.*, **36**, D154–D158.
- Matouk, I.J., DeGroot, N., Mezan, S., Ayyesh, S., Abu-lail, R., Hochberg, A. and Galun, E. (2007) The H19 non-coding RNA is essential for human tumor growth. *PLoS ONE*, **2**, e845.
- Cai, X. and Cullen, B.R. (2007) The imprinted H19 noncoding RNA is a primary microRNA precursor. *RNA*, **13**, 313–316.
- Kiss, T. (2002) Small nucleolar RNAs: an abundant group of noncoding RNAs with diverse cellular functions. *Cell*, **109**, 145–148.
- Xie, J., Zhang, M., Zhou, T., Hua, X., Tang, L. and Wu, W. (2007) Sno/scarRNAbase: a curated database for small nucleolar RNAs and cajal body-specific RNAs. *Nucleic Acids Res.*, **35**, D183–D187.
- Senoo, M., Matsumura, Y. and Habu, S. (2002) TAp63 γ (p51A) and dNp63 β (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. *Oncogene*, **21**, 2455–2465.
- Matoba, S., Kang, J.G., Patino, W.D., Wragg, A., Boehm, M., Gavrilova, O., Hurler, P.J., Bunz, F. and Hwang, P.M. (2006) p53 regulates mitochondrial respiration. *Science*, **312**, 1650–1653.
- The Gene Ontology (GO) project in 2006. (2006) *Nucleic Acids Res.*, **34**, D322–D326.
- Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., Katayama, T., Kawashima, S., Okuda, S., Tokimatsu, T. et al. (2008) KEGG for linking genomes to life and the environment. *Nucleic Acids Res.*, **36**, D480–D484.
- Iyer, N.V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, R.H., Gassmann, M., Gearhart, J.D., Lawler, A.M.,

- Yu, A.Y. *et al.* (1998) Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1 alpha. *Genes Dev.*, **12**, 149-162.
41. Matys, V., Kel-Margoulis, O.V., Fricke, E., Liebich, I., Land, S., Barre-Dirrie, A., Reuter, L., Chekmenev, D., Krull, M. *et al.* (2006) TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. *Nucleic Acids Res.*, **34**, D108-D110.
42. Johnson, D.S., Mortazavi, A., Myers, R.M. and Wold, B. (2007) Genome-wide mapping of in vivo protein-DNA interactions. *Science*, **316**, 1497-1502.
43. Barnes, W.M. (1994) PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. *Proc. Natl Acad. Sci. USA*, **91**, 2216-2220.
44. Wilhelm, B.T., Marguerat, S., Watt, S., Schubert, F., Wood, V., Goodhead, I., Penkett, C.J., Rogers, J. and Bahler, J. (2008) Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. *Nature*, **453**, 1239-1243.
45. Nagalakshmi, U., Wang, Z., Waern, K., Shou, C., Raha, D., Gerstein, M. and Snyder, M. (2008) The transcriptional landscape of the yeast genome defined by RNA sequencing. *Science*, **320**, 1344-1349.
46. Faulkner, G.J., Forrest, A.R., Chalk, A.M., Schroder, K., Hayashizaki, Y., Carninci, P., Hume, D.A. and Grimmond, S.M. (2008) A rescue strategy for multimapping short sequence tags refines surveys of transcriptional activity by CAGE. *Genomics*, **91**, 281-288.
47. Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G., Chepelev, I. and Zhao, K. (2007) High-resolution profiling of histone methylations in the human genome. *Cell*, **129**, 823-837.
48. Meissner, A., Mikkelsen, T.S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., Zhang, X., Bernstein, B.E., Nusbaum, C., Jaffe, D.B. *et al.* (2008) Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature*, **454**, 766-770.
49. Xi, H., Shulha, H.P., Lin, J.M., Vales, T.R., Fu, Y., Bodine, D.M., McKay, R.D., Chenoweth, J.G., Tesar, P.J., Furey, T.S. *et al.* (2007) Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome. *PLoS Genet.*, **3**, e136.
50. Marson, A., Levine, S.S., Cole, M.F., Frampton, G.M., Brambrink, T., Johnstone, S., Guenther, M.G., Johnston, W.K., Wernig, M., Newman, J. *et al.* (2008) Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. *Cell*, **134**, 521-533.



Contents lists available at ScienceDirect

Cancer Letters

journal homepage: www.elsevier.com/locate/canlet

Mini-review

Autophagy and cancer: Dynamism of the metabolism of tumor cells and tissues

Katsuya Tsuchihara^a, Satoshi Fujii^b, Hiroyasu Esumi^{a,*}^a Cancer Physiology Project, Research Center for Innovative oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan^b Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan

ARTICLE INFO

Article history:

Received 30 May 2008

Received in revised form 17 September 2008

Accepted 30 September 2008

Available online xxx

Keywords:

Autophagy

Tumor microenvironment

Energy metabolism

LC3

ABSTRACT

Autophagy is a dynamic process involving the bulk degradation of cytoplasmic organelles and proteins. Based on the function of "cellular recycling", autophagy plays key roles in the quality control of cellular components as well as supplying nutrients and materials for newly constructed structures in cells under metabolic stresses. The physiological relevance of autophagy in tumor formation and progression is still controversial. The cytoprotective function of autophagy in cells subjected to starvation might enhance the prolonged survival of tumor cells that are often exposed to metabolic stresses *in vivo*. Meanwhile, a tumor-suppressive function of autophagy has also been suggested. Autophagy-related cell death has been regarded as a primary mechanism for tumor suppression. In addition, the loss of autophagy induced genome instability and significant necrosis with inflammation in transplanted mouse tumor models, suggesting an additional function of autophagy in the suppression of tumor formation and growth. Until now, investigations supporting and proving the above possibilities have not been fully completed using clinical samples and equivalent animal models. Though monitoring and the interpretation of autophagy dynamism in tumor tissues are still technically difficult, identifying the autophagic activity in clinical samples might be necessary to clarify the pathophysiological relevance of autophagy in tumor formation and progression as well as to develop new therapeutic strategies based on the regulation of autophagy.

© 2008 Published by Elsevier Ireland Ltd.

1. Introduction – an overview of autophagy

Autophagy (from the Greek "auto", meaning oneself, and "phagy", meaning to eat) refers to a process in which cytoplasmic components are delivered to the lysosome for bulk degradation. Three types of autophagy – macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) – have been identified. These processes differ in the mode of delivery to lysosomes. Microautophagy involves the direct sequestration of cytosolic components by lysosomes. In CMA, a cytosolic and lysosomal chaperone protein, hsc70, assists unfolded proteins to translocate into lysosomes. In this review, we will focus

on the most widely investigated process: macroautophagy (herein referred to as autophagy) [1–5].

Autophagy is a conserved catabolic process that involves the sequestration of organelles and long-lived proteins residing in the cytoplasm into a unique organelle, the autophagosome. As shown in Fig. 1, an isolation membrane (also called a "phagophore") which is a double membrane consisting two parallel lipid bi-layers is formed and elongated. Isolation membranes start sequestering cytoplasmic constituents in the first step of autophagy. Once the edges of the isolation membrane are fused, it becomes a unique lipid bi-layer vesicular organelle, the autophagosome. Sequestered cytoplasmic components are completely engulfed by the autophagosome. Next, the autophagosome undergo a maturation process, in which the autophagosome fuses with early and late endosomes.

* Corresponding author. Tel.: +81 4 7133 1111; fax: +81 4 7134 6866.
E-mail address: hesumi@east.ncc.go.jp (H. Esumi).

Finally, matured autophagosomes fuse with the lysosome. The engulfed components, as well as the inner membrane of the autophagosome, are degraded by lysosomal hydrolases such as cathepsins. Autophagic processes have been well characterized in yeast, and more than 30 autophagy-related genes (ATG) that encode the proteins executing autophagy have been identified in the field of yeast genetics [6]. Similar autophagic machineries have been observed in mammalian cells, and mammalian orthologs for ATGs and other autophagy regulating molecules have also been identified [7]. The detailed molecular events involved in these processes are described in another comprehensive review [8].

Compared with the ubiquitin–proteasome system, which recognizes specific targets for degradation, autophagy has been thought to engulf cytoplasmic constituents non-selectively. Recently, selective sequestration targeting specific organelles or invasive microbes has also attracted attention [9].

A very concise description of the function of autophagy is recycling: reducing waste and yielding resources. Damaged organelles and misfolded proteins accumulate in senescent cells or cells under various stresses, such as oxidative stress and infection. The autophagic machinery degrades and reduces this cellular “garbage”. This function is particularly effective in postmitotic cells, like neurons and cardiac myocytes, since these cells cannot dilute such superfluous components by undergoing cell division. Basal autophagy is constitutively observed in these postmitotic cells and may have an important function for the quality control of cellular components [10]. On the other hand, self-digested components provide nutrients and materials for newly constructed cellular structures. The amino acids and fatty acids generated by autophagic degradation are used by the tricarboxylic acid (TCA) cycle to produce ATP, a main energy source for various cellular events. Methylpyruvate, a membrane-permeable derivative of pyruvate that serves as a substrate for the TCA cycle, restored ATP production in autophagy-deficient cells. Furthermore, supplementation with methylpyruvate rescued these cells from metabolic stress-induced cell death [11].

Observations of clinical samples and animal and cellular models have suggested a variety of physiological and pathological roles of autophagy, such as development, aging, host defense system, neurodegenerative diseases, muscle and cardiac diseases and cancer [12,13]. However, the relevance of autophagy in tumor formation and progression is still controversial. Although previous findings strongly suggest that autophagy contributes to sustainable cell survival, anti-tumorigenic roles of autophagy have been also mentioned. Here, we will summarize and discuss recent studies of autophagy in cancer biology with the goal of clarifying this issue.

2. Autophagy protects cancer cells from starvation

Cancer cells in solid tumors obtain their necessary nutrients from blood flow. Aberrantly proliferating cancer cells may have high bioenergetic demands and require more nutrients than non-cancerous cells. Tumor angiogen-

esis is a reasonable way to increase blood flow. During the initial phase of tumorigenesis, tumor vessels have not yet been induced and the nutritional demands of tumor cells are likely to surpass the supply from normal vasculature. Moreover, even after tumor vessels have been established, the oxygen tension and glucose concentration in locally advanced tumors remain at a low level. This suggests that the tumor microvasculature is functionally and structurally immature to support sufficient blood flow [14–16]. Or, even once functionally and structurally adequate tumor vessels were established, soon or later, the balance of supply and demand would be ruined by disorganized tumor cell proliferation resulting in the disastrous dysfunction of the tumor vessels. The reduction of functional blood flow is significant in clinically hypovascular tumors such as pancreatic cancers [17]. Under these conditions, cancer cells are likely to encounter chronic ischemia leading to a shortage of nutrients. Cancer cells might adapt themselves to such a harsh microenvironment. In experimental cell culture systems, several cancer cells were resistant to nutrient-deprived conditions. For example, several pancreatic cancer- and colorectal cancer-derived cell lines showed a survival rate of more than 50% after 48 h of culture in a medium completely lacking carbon and nitrogen sources. Contrastingly, non-transformed fibroblasts were completely abolished within a day under the same conditions [18]. These findings suggest that cancer cells use alternative metabolic processes for their survival under starved conditions.

Metabolic stresses reportedly induce apoptosis [19]. In many tumor cells, apoptosis is suppressed by the overexpression of anti-apoptotic molecules or by the lack of pro-apoptotic molecules. Less apoptosis may explain the limited death of cancer cells under metabolic stresses, but the manner in which cancer cells obtain their necessary nutrients remains a mystery. One possible solution is that the cells digest their own components and obtain amino acids as an alternative energy source. Autophagy seems ideal for cancer cells to maintain energy homeostasis in such an autonomous fashion. Autophagy is known to be induced by different forms of metabolic stress, including nutrient deprivation, growth factor deprivation, and hypoxia [13,20]. Since these conditions are often observed in physiological tumor microenvironments, autophagy is likely activated in cancer cells.

We should also remind the apparent discrepancy between the tumor “cell” doubling time and the tumor “volume” doubling time. The potential tumor cell doubling time estimated by *in vivo* measurement of S-phase duration was remarkably rapid in many solid tumors, a median value of the order of 5 days. However, tumor volume doubling time determined by radiological measurement of the size of these tumors was much slower, months or years [21,22]. It suggests that about half of the proliferating cancer cells are subsequently lost under tumor microenvironment though many of them have already acquired anti-apoptotic function. Is there any physiological relevance of such dynamism of cell kinetics? A potential scenario is that the vanishing cells serve nutritional sources for surrounding surviving cells. In this sense, inducing cell death and supporting cell survival under metabolic stresses are not

contradicting. Autophagy is also known to induce cell death and possibly sacrifice some part of individual tumor cell for supporting a prolonged survival and continuous growth of other cells in the tumor mass.

Several experimental methods have been used to identify the activation of autophagy (Table 1) [23]. Measuring the turnover of long-lived proteins provides a biochemical clue to autophagy. Transmission electron microscopy reveals the ultrastructure characteristics of the autophagosome. Autophagosome formation is also conveniently monitored by following a phosphatidylethanolamine (PE)-conjugated form of yeast Atg8 or mammalian LC3, one of the mammalian orthologs of Atg8. During autophagy, LC3 shifts from a soluble form to a membrane-bound form (LC3-II) and is incorporated into the autophagosomal inner membrane. The existence of autophagosome-incorporated LC3-II can be detected biochemically (immunoblotting against LC3) or microscopically (immunocytochemistry against LC3 or exogenously expressed, fluorescently tagged LC3).

The ultrastructure of autophagosomes in tumor cells has been observed in several experimental systems, including a rat pancreatic cancer model [24]. A high potential for autophagic protein degradation was observed in an undifferentiated colon cancer cell line, HT29, and other transformed cells [25]. Nutrient deprivation-induced LC3-II turnover was observed in colorectal cancer-derived cell lines that showed resistance to starvation [26]. In addition to these findings in cultured cancer cells, the increased expression of autophagy-related proteins, including BNP3 and LC3, was observed specifically in colorectal and gastric cancer epithelia in surgically-resected specimens [26,27].

Increasing evidence implies that autophagy has a cytoprotective role in cancer cells under metabolic stress. Transplanted epithelial tumors in which the Beclin 1 or Atg5 alleles were deleted showed a reduction in autophagy and an increase in cell death in regions exposed to meta-

bolic stress [28–30]. Similarly, a cytoprotective function of autophagy was observed in cultured cancer cells. The genetic inactivation of autophagy by the suppression of ATG expression using RNA interference or the constitutive activation of PI3K induced cell death in response to metabolic stresses [28–30]. RNA interference of ATG5, Beclin 1 and ATG7 enhanced tamoxifen-induced apoptosis in tamoxifen-resistant breast cancer cell lines [31]. ATG5 knock-down also enhanced the effect of alkylating drug-induced cell death [32]. The pharmacological inhibition of autophagy also induced nutrient deprivation-induced cell death [26]. Chloroquine, which interferes with lysosomal function, inhibited autophagy and suppressed Myc-induced lymphomagenesis in a transgenic mouse model [32].

Though the above findings suggest that autophagy may contribute to tumor cell survival and tumor formation, the molecular mechanisms underlying the acquisition of vigorous autophagic activity in cancer cells have remained unclear. Recently, Kroemer and his colleagues reported a potential anti-autophagic function of cytoplasm-localizing p53 [33]. They observed the degradation of p53 under metabolic stresses followed by the induction of autophagy. Contrastingly, the loss of p53 resulted in the consistent activation of autophagy in a series of cell lines. While overexpression of wild-type p53 reduced the aberrant autophagosome formation, a mutant p53 protein which harbors a codon 175 mutation (R175H), which is frequently identified in clinical human cancers, did not affect the higher basal autophagic activity of p53-null cells. Though most of their observation was limited in the culture cell system, further studies which clarify its relevance to tumor formation and progression are awaited.

3. Autophagy and tumor suppression

An opposite perspective was presented by a study examining a Bcl-2-binding protein, Beclin 1. Levine and

Table 1
Recommended methods for monitoring autophagy in higher eukaryotes [23].

| Criteria | Methods |
|--|---|
| <i>Monitoring phagophore and autophagosome formation by steady state methods</i> | |
| 1. Electron microscopy (increase in autophagosome quantity) | Quantitative electron microscopy, immunoelectron microscopy |
| 2. Atg8/LC3 Western blotting and ubiquitin-like protein conjugation systems (increase in the amount of LC3-II, and Atg12-Atg5 conjugation) | Western blot |
| 3. Fluorescence microscopy (increase in punctate LC3 (or Atg18)) | Fluorescence, immunofluorescence and immunoelectron microscopy |
| 4. TOR and Atg1 kinase activity | Western blot, immunoprecipitation or kinase assays |
| 5. Transcriptional regulation | Northern blot or qRT-PCR |
| <i>Monitoring autophagy by flux measurements</i> | |
| 1. Autophagic protein degradation | Turnover of long-lived proteins |
| 2. Turnover of LC3-II | Western blot +/- lysosomal fusion or degradation inhibitors |
| 3. GFP-Atg8/LC3 lysosomal delivery, and proteolysis (to generate free GFP) | Fluorescence microscopy, FACS Western blot +/- lysosomal fusion or degradation inhibitors |
| 4. p62 Western blot | Western blot with qRT-PCR or Northern blot to assess transcription |
| 5. Autophagic sequestration assays | Lysosomal accumulation by biochemical or multilabel fluorescence techniques |
| 6. Turnover of autophagic compartments | Electron microscopy morphometry/stereology |
| 7. Autophagosome-lysosome colocalization and dequenching assay | Fluorescence microscopy |
| 8. Sequestration and processing assays in plants | Chimeric RFP fluorescence and processing, light and electron microscopy |
| 9. Tandem mRFP-GFP fluorescence microscopy | Fluorescence microscopy of tandem mRFP-GFP-LC3 |
| 10. Tissue fractionation | Centrifugation, Western blot and electron microscopy |
| 11. Analyses in vivo | Fluorescence microscopy and immunohistochemistry |

her colleagues first identified Beclin 1, a mammalian ortholog of ATG6, as a candidate tumor suppressor. Beclin 1 interacts with class III PI3-kinase, Vps34, and this interaction was crucial for the induction of autophagy and suppression of the growth of the xenografted breast cancer cell lines [34–36]. Vps34 is also required for normal protein trafficking pathways such as the delivery of proteases from the trans-Golgi network to the lysosomes. Atg6 (Vsp30) was reportedly involved in the regulation of both autophagy and endosomal membrane trafficking in yeast. Whether mammalian Beclin 1 takes part in the membrane trafficking is still controversial [34,35].

The hemiallelic loss of the Beclin 1 coding gene was observed in 40–75% of sporadic human cancers in the breast, ovary and prostate [37]. A gene-targeted mouse model of Beclin 1 provided another clue [38,39]. The homozygous deletion of Beclin 1 led to embryonic lethality. Meanwhile, Beclin 1 heterozygous mutant mice showed decreased autophagy and increased spontaneous tumors, including lung and liver cancers and lymphomas. In these mice, no loss of heterozygosity (LOH) was observed and the remaining wild-type allele of Beclin 1 was intact. Furthermore, Beclin 1 protein expression was reduced but not completely diminished in mouse tumors as well as human clinical samples [36]. These findings suggest that Beclin 1 is a haplo-insufficient tumor-suppressor gene. The tumor-suppressive function of Beclin 1 was reinforced by the relevance of Beclin 1-associated proteins to tumor suppression. UVRAG was initially identified from the cDNA library, which partially rescued the UV sensitivity of a

xeroderma pigmentosum (XP) cell line. The screening of Beclin 1-binding proteins revealed that UVRAG was recruited to the Beclin 1–class III PI3K complex. UVRAG activated Beclin 1 and induced autophagosome formation [40]. In addition, UVRAG is involved in autophagosome maturation. UVRAG interacts with class C tethering proteins (Vps11, Vps16, Vps18 and Vps33) resulting in activation of a small GTPase, Rab7 which enhances the fusion of autophagosomes to endosomes [41]. As seen with Beclin 1, UVRAG is monoallelically mutated in human colorectal cancers [40]. Bif-1 (also known as Endophilin B1) interacts with Beclin 1 through UVRAG. Bif-1 activated class III PI3K and induced autophagy. Spontaneous tumor formation was increased in Bif-1 deficient mice [42].

During investigations of autophagy in mammalian cells, several signaling pathways have been revealed to regulate autophagy. Interestingly, correlations between pro-autophagic molecules and tumor suppressors and between anti-autophagic molecules and oncogene products can be pointed out (Fig. 1). The mammalian target of rapamycin (mTOR) is a key molecule for regulating cancer cell proliferation. Rapamycin inhibits mTOR function followed by autophagy induction [11,43]. Molecules known to suppress mTOR, including PTEN and TSC, both of which are regarded as tumor-suppressor gene products, induce autophagy [44,45]. Meanwhile, mTOR-activating molecules like class I PI3K and Akt, which are frequently activated in various cancer cells, inhibit autophagy [11,46]. The involvement of p53 in the activation of autophagy has also been suggested. In contrast to the inhibitory effect of cytoplasmic p53 men-




Fig. 1. Cellular events during autophagy (macroautophagy). In the first step of autophagy, the isolation membrane (phagophore) is elongated and sequesters the cytoplasmic constituents. Fusion of the edges of the isolation membrane forms an autophagosome, which contains the sequestered components. A lysosome then fuses with the autophagosome, and lysosomal hydrolases degrade the engulfed components along with the inner membrane of the autophagosome. Mammalian homologues of ATG (autophagy-related genes) have been identified. Class I PI3K and mTOR signaling inhibits autophagy activation, whereas tumor-suppressor proteins like p53 and PTEN induce autophagy. Rapamycin inhibits mTOR and induces autophagy. 3-Methyladenine, chloroquine, bafilomycin A1, E64d and pepstatin A inhibit autophagy at different points. These small molecules are used to inhibit autophagy in experimental model systems.

tioned above, the transactivating function of nuclear p53 takes a role in the autophagy induction. DRAM is a direct transcriptional target of p53, and its product localizes in the lysosomal membrane. The activation of p53 induced an increase in autophagy in a DRAM-dependent manner [47]. p53 was also reported to affect autophagy via the suppression of mTOR [45]. DAPk, death-associated protein kinase, induces autophagy as well as apoptosis. The tumor-suppressive function of DAPk has also been described, and promoter hypermethylation of the DAPk locus has been reported in several human cancers [48].

These findings suggest the likely relevance of autophagy to tumor suppression. However, the above-mentioned pro- and anti-autophagic molecules, like p53 and mTOR, are pluripotent proteins that regulate cell proliferation and death via various molecular events. The net contribution of autophagy to cell fate decisions during tumorigenesis should be carefully estimated, but this objective has not yet been successfully accomplished.

4. Autophagy and cell death

Autophagy has attracted much attention in connection with cell death. "Type II" or "autophagic" non-apoptotic programmed cell death is morphologically defined by the existence of autophagosomes [49]. Autophagic death has been reported in cancer cells, especially those that have been treated with chemotherapeutic or radiotherapeutic agents [50]. This cytotoxic effect has been supposed to be the main reason for the tumor-suppressive function of autophagy. Self-cannibalism, that is, the situation in which excess autophagic catabolism exceeds the capacity for cel-

lular anabolism, is frequently argued as a potential mechanism for autophagic death. Though autophagy has been regarded to degrade cytoplasmic constituents non-specifically, the specific autophagic degradation of target proteins and organelles has also been reported. The specific degradation of cytoprotective factors is another undeniable mechanism of autophagic death [51]. However, experimental evidence supporting these ideas has not yet been obtained. Moreover, cytotoxic stimuli, such as oxidative stress, induces both autophagy and cell death, but whether autophagy is an active death-inducing mechanism (cell death by autophagy) or a result of an unsuccessful effort to prolong the survival of damaged cells (cell death with autophagy) is difficult to distinguish.

Recent findings have raised a question about the relevance of autophagic death to tumor suppression. The allelic loss of Beclin 1 inhibited both basal and stress-induced autophagy in immortalized baby mouse kidney epithelial cells. Metabolic stress-induced cell death was apparently increased, suggesting loss of autophagy led impaired cytoprotective function. Despite impairment in autophagy-mediated cell survival, Beclin 1+/- cells were more tumorigenic than the wild-type control cells [28]. To make a plausible explanation for these contradictory findings, the loss of cytoprotection induces tumorigenesis, is still challenging.

5. Potential mechanisms for the tumor-suppressive function of autophagy

Recently, White and colleagues have proposed interesting hypotheses about the above issues (Fig. 2). Under meta-




Fig. 2. Both the gain and loss of autophagy are possibly involved in tumor formation and growth. The activation of autophagy supplies nutrients to tumor cells under metabolic stress. On the other hand, the eradication of tumor cells by autophagy-related cell death is assumed to occur, and the loss of autophagy may lead to tumor cell survival. A recent mouse model using transplanted autophagy-deficient tumor cells revealed that the loss of autophagy induced DNA damage and inflammation, enhancing tumor formation and growth.

bolic stress, Beclin 1+/- epithelial cells overexpressing anti-apoptotic Bcl-2 showed an increase in DNA double strand breaks, gene amplification, and chromosomal number disorder. They assumed that the loss of autophagy induces DNA damage and chromosomal instability, followed by increased tumor susceptibility [30]. The exact mechanisms for how autophagy maintains genome stability remain unclear. One possibility is that cells lacking autophagy are unable to reduce damaged mitochondria and peroxisomes. These damaged organelles are potential sources of reactive oxygen species that induce genotoxic stress.

When the same autophagy-deficient epithelial cells were exposed to starvation, apparent necrotic cell death was observed when apoptosis was inhibited. Furthermore, significant inflammation was induced in the tumor tissues in which autophagy-deficient cells were transplanted [28]. Necrosis is often associated with macrophage infiltration *in vivo*, and tumor-associated macrophages enhance tumor progression [52]. It is an interesting hypothesis that the inflammation induced by a lack of autophagy may be correlated with tumor progression *in vivo*.

The above scenarios are not incompatible with the idea that autophagy protects cancer cells from metabolic stress-induced death, and these potential mechanisms are worthy of further discussion to elucidate the physiological roles of autophagy in tumorigenesis.

6. Perspective – remaining tasks

The relevance of autophagy to cancer remains a frustrating topic to discuss. It is necessary to understand the consequences of the loss or gain of autophagy in the context of the tumor microenvironment. Previously proposed hypotheses for how autophagy contributes to tumor biology, either pro- or anti-tumorigenic, are possible and interesting, but most of them have arisen from artificial experimental systems and no direct clinico-pathological evidence supports these ideas. Evaluating autophagy in clinical tumor samples has been difficult, mainly because of the lack of appropriate markers for detecting active autophagy. Autophagosome formation in tumor tissues has been morphologically confirmed using electron microscopy, but this method is not suitable for handling a large number of specimens. Recently, anti-LC3 antibodies for immunostaining have become available [26,53,54]. LC3-II proteins incorporated into autophagosome membranes exhibit a punctuate cytoplasmic staining pattern during active autophagy. LC3 immunostaining is an easier method of evaluating autophagosome formation in conventional formaldehyde-fixed surgically-resected specimens. We applied polyclonal anti-LC3 antibody for the immunostaining of colorectal cancer specimens. In over 90% of the cases, LC3 accumulated specifically in cancerous epithelia but not in adjacent non-cancerous mucosa [26]. Similar cancer-specific accumulation of LC3 was observed in pancreatic cancer. Interestingly, strong LC3 expression in the peripheral area of cancer tissue was correlated with a poor prognosis (Fig. 3) [55]. As we mentioned earlier, both pancreatic and colorectal cancer-derived cell lines are often resistant to the nutrient-starvation. It seems

more than coincidence that specific LC3 accumulation was observed in the clinical samples of these tumors. Further investigation using various cancer tissue samples may reveal the contribution of the gain or loss of autophagy in tumor formation and progression more clearly.

Autophagy is executed by dynamic and multiple cellular processes, including the formation of the autophagosome, the delivery of cytoplasmic constituents to the lysosome, and the digestion and recycling of these target molecules and organelles. For the precise evaluation of autophagic activity, the "autophagic flux" must be estimated. For example, the accumulation of autophagosomes reflects either an increase in autophagosome formation (activation of autophagy) or a reduction in the degradation of autophagosomes (inhibition of autophagy). To determine the flux, the rate of long-lived protein degradation must be measured or the changes in appropriate autophagy markers, such as the LC3-II protein level, must be assessed with or without the arrest of autophagic flux at a given point of blockage. Recently, Klionsky and 231 other scientists published guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes (Table 1) [23]. In these guidelines, the authors strongly recommended the measurement of autophagic flux for monitoring autophagy. Detecting autophagosome formation using steady state methods, including electron microscopy or LC3 immunostaining, should be combined with flux measurements. However, applying such dynamic assays to clinical samples is often technically difficult.

The above-mentioned guidelines do not provide a full resolution of the above difficulties. Further discussion might be needed to establish standard methods for evaluating autophagy in clinical samples. To assess autophagic activity using steady state methods, not only one parameter, but multiple autophagy-related molecules should be applied. For example, while the loss of Beclin 1 implies a reduction in autophagosome formation, this outcome should be confirmed by a decrease in autophagosome-specific markers, such as LC3-II. Mimicking *in vivo* events on *ex vivo* systems may support the findings obtained in clinical samples using steady state methods. In such cases, it should be remembered that autophagy is induced under complex microenvironments in cancer tissues. As mentioned previously, cancer cells are often exposed to chronic ischemia. Under this situation, not only nutrients but also oxygen, growth factors and other components provided by blood flow might be decreased. Meanwhile, metabolites and other components excreted from cancer cells may not be properly removed from the cancer tissues. Cancer cells are also directly and indirectly influenced by surrounding stromal cells and extracellular matrices. Reconstituting all these factors in an experimental cell culture system is practically unfeasible, but the above restrictions should always be taken into account when evaluating the results obtained from any model system.

To analyze autophagy function under more physiological conditions, appropriate animal models are eagerly needed. Xenografted and/or isografted animals in which the transplanted transformed cells lacking autophagy-related genes are useful, but not perfect. Transplanted tumors do not always reproduce the microenvironmental




Fig. 3. Autophagosome formation in the surgically-resected specimens. (A) Autophagosome-incorporated LC3 protein was detected using GFP-LC3 fusion protein in a cultured colorectal cancer cell line, SW480, during amino acid-deprivation. (B) Tumor cell-specific LC3 accumulation in colorectal cancer tissue was detected using immunohistochemistry with anti-LC3 antibody and hematoxylin and eosin staining. (C) LC3 accumulation at the peripheral area of the pancreatic cancer tissue. Nv: nerve cells in which LC3 is constitutively expressed. (inlet) Higher magnification of (B) and (C). LC3 proteins were localized in the cytoplasm with irregular condensation. (D) The group with strongly positive expression of LC3 protein in the peripheral area of the pancreatic cancer tissue had a significantly shorter survival time. (A) and (B) are quoted from Ref. [26], (C) and (D) are quoted from Ref. [55].

conditions of clinical tumors. Furthermore, such models do not provide information regarding the initial steps of tumorigenesis, in which autophagy might have critical roles for pampering aberrantly proliferating cancer cells without extra blood supply. Examining the effect of various autophagy inhibitors in tumorigenic animals is another way to evaluate the roles of autophagy *in vivo*. But it has the drawback that these reagents are not completely autophagy-specific [32]. Recently, several genetically engineered mouse models targeting autophagy-related genes have been reported [12]. However, these mice often show embryonic or neonatal lethality, hampering the long-term observation of tumorigenesis in adult animals. Tissue-specific or inducible conditional knockout systems may be useful for this purpose.

Whether the control of autophagy is useful for cancer therapy and prevention is another important issue. Several small molecules are known to activate or inhibit autophagy (Fig. 1) [56]. Inhibiting the class I PI3K-mTOR axis by rapamycin induces autophagy. The inhibition of autophagy can be achieved by targeting several points. A class III PI3K inhibitor (3-methyladenine), lysosomotropic alkalines (chloroquine and 3-hydroxychloroquine), a lysosomal proton pump inhibitor (bafilomycin A1) and lysosomal enzyme inhibitors (E64d and pepstatin A) are available for experimental use. Since the contribution of autophagy to tumorigenesis is still controversial, we should carefully consider the application of autophagy inhibitors or activators for therapeutic use. Increasing evidence emphasizes the importance of basal autophagy for cellular quality control [57]. The disturbance of autophagy might result in unexpected adverse effects, especially in postmitotic cells in the central nervous system and cardiovascular system. The specificity of such activators and inhibitors is another

issue to consider. The above-mentioned chemicals are not autophagy-specific. Also, the targeted kinases (PI3K, mTOR) or organelles (lysosome) have broad functions other than autophagy regulation.

In the last decade, autophagy has appeared in the center stage of cancer biology and is now attracting much attention in the development of new cancer therapeutics. As mentioned above, a considerable number of issues remain to be clarified. However, similar to its molecular process, the research field of autophagy is very dynamic. Novel strategies for monitoring autophagy and experimental models are appearing, and various small molecules regulating autophagic process will be available. Further investigation will reveal the dynamism of metabolism in cancer cells and tissues that is still behind the scene now. And it will likely open up a new field of cancer biology.

Conflicts of interest statement

None declared.

Acknowledgements

This work was supported by Grants for the Third-Term Comprehensive 10-Year Strategy for Cancer Control, and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare and a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology – Japan.

References

- [1] D.J. Klionsky, The molecular machinery of autophagy: unanswered questions, *J. Cell Sci.* 118 (2005) 7–18.

- [2] D.J. Klionsky, Autophagy: from phenomenology to molecular understanding in less than a decade, *Nat. Rev. Mol. Cell Biol.* 8 (2007) 931-937.
- [3] B. Levine, D.J. Klionsky, Development by self-digestion: molecular mechanisms and biological functions of autophagy, *Dev. Cell* 6 (2004) 463-477.
- [4] N. Mizushima, Autophagy: process and function, *Genes Dev.* 21 (2007) 2861-2873.
- [5] N. Mizushima, D.J. Klionsky, Protein turnover via autophagy: implications for metabolism, *Annu. Rev. Nutr.* 27 (2007) 19-40.
- [6] D.J. Klionsky, J.M. Cregg, W.A. Dunn Jr., S.D. Emr, Y. Sakai, I.V. Sandoval, A. Sibirny, S. Subramani, M. Thumm, M. Veenhuis, Y. Ohsumi, A unified nomenclature for yeast autophagy-related genes, *Dev. Cell* 5 (2003) 539-545.
- [7] P. Codogno, A.J. Meijer, Autophagy and signaling: their role in cell survival and cell death, *Cell Death Differ.* 12 (Suppl. 2) (2005) 1509-1518.
- [8] Z. Xie, D.J. Klionsky, Autophagosome formation: core machinery and adaptations, *Nat. Cell Biol.* 9 (2007) 1102-1109.
- [9] L. Yu, L. Strandberg, M.J. Lenardo, The selectivity of autophagy and its role in cell death and survival, *Autophagy* 4 (2008).
- [10] M. Komatsu, T. Ueno, S. Waguri, Y. Uchiyama, E. Kominami, K. Tanaka, Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons, *Cell Death Differ.* 14 (2007) 887-894.
- [11] J.J. Lum, D.E. Bauer, M. Kong, M.H. Harris, C. Li, T. Lindsten, C.B. Thompson, Growth factor regulation of autophagy and cell survival in the absence of apoptosis, *Cell* 120 (2005) 237-248.
- [12] B. Levine, G. Kroemer, Autophagy in the pathogenesis of disease, *Cell* 132 (2008) 27-42.
- [13] N. Mizushima, B. Levine, A.M. Cuervo, D.J. Klionsky, Autophagy fights disease through cellular self-digestion, *Nature* 451 (2008) 1069-1075.
- [14] A.L. Harris, Hypoxia - a key regulatory factor in tumour growth, *Nat. Rev. Cancer* 2 (2002) 38-47.
- [15] R.K. Jain, Molecular regulation of vessel maturation, *Nat. Med.* 9 (2003) 685-693.
- [16] P. Vaupel, O. Thews, M. Hoekel, Treatment resistance of solid tumors: role of hypoxia and anemia, *Med. Oncol.* 18 (2001) 243-259.
- [17] M. Kitano, M. Kudo, K. Maekawa, Y. Suetomi, H. Sakamoto, N. Fukuta, R. Nakaoka, T. Kawasaki, Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography, *Gut* 53 (2004) 854-859.
- [18] K. Izuishi, K. Kato, T. Ogura, T. Kinoshita, H. Esumi, Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy, *Cancer Res.* 60 (2000) 6201-6207.
- [19] D.A. Nelson, T.T. Tan, A.B. Rabson, D. Anderson, K. Degenhardt, E. White, Hypoxia and defective apoptosis drive genomic instability and tumorigenesis, *Genes Dev.* 18 (2004) 2095-2107.
- [20] G.L. Semenza, Mitochondrial autophagy: life and breath of the cell, *Autophagy* 4 (2008).
- [21] S. Friberg, S. Mattson, On the growth rates of human malignant tumors: implications for medical decision making, *J. Surg. Oncol.* 65 (1997) 284-297.
- [22] D.A. Rew, G.D. Wilson, Cell production rates in human tissues and tumours and their significance. Part II: clinical data, *Eur. J. Surg. Oncol.* 26 (2000) 405-417.
- [23] K. Heidenreich, J.A. Hill, M. Hoyer-Hansen, X. Hu, W.P. Huang, A. Iwasaki, M. Jaattela, W.T. Jackson, X. Jiang, S. Jin, T. Johansen, J.U. Jung, M. Kadowaki, C. Kang, A. Kelekar, D.H. Kessel, J.A. Kiel, H.P. Kim, A. Kimchi, T.J. Kinsella, K. Kiselyov, K. Kitamoto, E. Knecht, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes, *Autophagy* 4 (2008) 151-175.
- [24] G. Rez, S. Toth, Z. Palfi, Cellular autophagic capacity is highly increased in azaserine-induced preneoplastic atypical acinar nodules, *Carcinogenesis* 20 (1999) 1893-1898.
- [25] E. Ogier-Denis, J.J. Houri, C. Bauvy, P. Codogno, Guanine nucleotide exchange on heterotrimeric G13 protein controls autophagic sequestration in HT-29 cells, *J. Biol. Chem.* 271 (1996) 28593-28600.
- [26] K. Sato, K. Tsuchihara, S. Fujii, M. Sugiyama, T. Goya, Y. Atomi, T. Ueno, A. Ochiai, H. Esumi, Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation, *Cancer Res.* 67 (2007) 9677-9684.
- [27] S.H. Lee, E.G. Jeong, N.J. Yoo, Mutational and expression analysis of BNIP3, a pro-apoptotic Bcl-2 member, in gastric carcinomas, *APMIS* 115 (2007) 1274-1280.
- [28] K. Degenhardt, R. Mathew, B. Beaudoin, K. Bray, D. Anderson, G. Chen, C. Mukherjee, Y. Shi, C. Gelinas, Y. Fan, D.A. Nelson, S. Jin, E. White, Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis, *Cancer Cell* 10 (2006) 51-64.
- [29] V. Karantzis-Wadsworth, S. Patel, O. Kravchuk, G. Chen, R. Mathew, S. Jin, E. White, Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis, *Genes Dev.* 21 (2007) 1621-1635.
- [30] R. Mathew, S. Kongara, B. Beaudoin, C.M. Karp, K. Bray, K. Degenhardt, G. Chen, S. Jin, E. White, Autophagy suppresses tumor progression by limiting chromosomal instability, *Genes Dev.* 21 (2007) 1367-1381.
- [31] M.A. Qadir, B. Kwok, W.H. Dragowska, K.H. To, D. Le, M.B. Bally, S.M. Gorski, Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization, *Breast Cancer Res. Treat.* (2008).
- [32] R.K. Amaravadi, D. Yu, J.J. Lum, T. Bui, M.A. Christophorou, G.I. Evan, A. Thomas-Tikhonenko, C.B. Thompson, Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma, *J. Clin. Invest.* 117 (2007) 326-336.
- [33] E. Tasdemir, M.C. Maiuri, L. Galluzzi, I. Vitale, M. Djavaheri-Mergny, M. D'Amelio, A. Criollo, E. Morselli, C. Zhu, F. Harper, U. Nannmark, C. Samara, P. Pinton, J.M. Vicencio, R. Carnuccio, U.M. Moll, F. Madeo, P. Paterlini-Brechot, R. Rizzuto, G. Szabadkai, G. Pierron, K. Blomgren, N. Tavernarakis, P. Codogno, F. Cecconi, G. Kroemer, Regulation of autophagy by cytoplasmic p53, *Nat. Cell Biol.* 10 (2008) 676-687.
- [34] N. Furuya, J. Yu, M. Byfield, S. Pattingre, B. Levine, The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function, *Autophagy* 1 (2005) 46-52.
- [35] X. Zeng, J.H. Overmeyer, W.A. Maltese, Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking, *J. Cell Sci.* 119 (2006) 259-270.
- [36] X.H. Liang, S. Jackson, M. Seaman, K. Brown, B. Kempkes, H. Hibshoosh, B. Levine, Induction of autophagy and inhibition of tumorigenesis by beclin 1, *Nature* 402 (1999) 672-676.
- [37] V.M. Aita, X.H. Liang, V.V. Murty, D.L. Pincus, W. Yu, E. Cayanis, S. Kalachikov, T.C. Gilliam, B. Levine, Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21, *Genomics* 59 (1999) 59-65.
- [38] X. Qu, J. Yu, G. Bhagat, N. Furuya, H. Hibshoosh, A. Troxel, J. Rosen, E.L. Eskelinen, N. Mizushima, Y. Ohsumi, G. Cattorelli, B. Levine, Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene, *J. Clin. Invest.* 112 (2003) 1809-1820.
- [39] Z. Yue, S. Jin, C. Yang, A.J. Levine, N. Heintz, Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor, *Proc. Natl. Acad. Sci. USA* 100 (2003) 15077-15082.
- [40] C. Liang, P. Feng, B. Ku, I. Dotan, D. Canaan, B.H. Oh, J.U. Jung, Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG, *Nat. Cell Biol.* 8 (2006) 688-699.
- [41] C. Liang, J.S. Lee, K.S. Inn, M.U. Gack, Q. Li, E.A. Roberts, I. Vergne, V. Deretic, P. Feng, C. Akazawa, J.U. Jung, Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosomal maturation and endocytic trafficking, *Nat. Cell Biol.* 10 (2008) 776-787.
- [42] Y. Takahashi, D. Coppola, N. Matsushita, H.D. Cuaing, M. Sun, Y. Sato, C. Liang, J.U. Jung, J.Q. Cheng, J.J. Mul, W.J. Pledger, H.G. Wang, Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis, *Nat. Cell Biol.* 9 (2007) 1142-1151.
- [43] B. Ravikumar, C. Vacher, Z. Berger, J.E. Davies, S. Luo, L.G. Oroz, F. Scaravilli, D.F. Easton, R. Duden, C.J. O'Kane, D.C. Rubenstein, Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease, *Nat. Genet.* 36 (2004) 585-595.
- [44] S. Arico, A. Petiot, C. Bauvy, P.F. Dubbelhuis, A.J. Meijer, P. Codogno, E. Ogier-Denis, The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway, *J. Biol. Chem.* 276 (2001) 35243-35246.
- [45] Z. Feng, H. Zhang, A.J. Levine, S. Jin, The coordinate regulation of the p53 and mTOR pathways in cells, *Proc. Natl. Acad. Sci. USA* 102 (2005) 8204-8209.
- [46] H. Takeuchi, Y. Kondo, K. Fujiwara, T. Kanazawa, H. Anki, G.B. Mills, S. Kondo, Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors, *Cancer Res.* 65 (2005) 3336-3346.
- [47] D. Crighton, S. Wilkinson, J. O'Prey, N. Syed, P. Smith, P.R. Harrison, M. Gasco, O. Garrone, T. Crook, K.M. Ryan, DRAM, a p53-induced modulator of autophagy, is critical for apoptosis, *Cell* 126 (2006) 121-134.

- [48] B. Inbal, S. Bialik, I. Sabanay, G. Shani, A. Kimchi, DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death, *J. Cell Biol.* 157 (2002) 455–468.
- [49] P.G. Clarke, Developmental cell death: morphological diversity and multiple mechanisms, *Anat. Embryol. Berl.* 181 (1990) 195–213.
- [50] Y. Kondo, T. Kanzawa, R. Sawaya, S. Kondo, The role of autophagy in cancer development and response to therapy, *Nat. Rev. Cancer* 5 (2005) 726–734.
- [51] M.C. Maiuri, E. Zalckvar, A. Kimchi, G. Kroemer, Self-eating and self-killing: crosstalk between autophagy and apoptosis, *Nat. Rev. Mol. Cell Biol.* 8 (2007) 741–752.
- [52] A. Mantovani, T. Schioppa, C. Porta, P. Allavena, A. Sica, Role of tumor-associated macrophages in tumor progression and invasion, *Cancer Metastasis Rev.* 25 (2006) 315–322.
- [53] H. Aoki, Y. Kondo, K. Aldape, A. Yamamoto, E. Iwado, T. Yokoyama, E.F. Hollingsworth, R. Kobayashi, K. Hess, N. Shinojima, T. Shingu, Y. Tamada, L. Zhang, C. Conrad, O. Bogler, G. Mills, R. Sawaya, S. Kondo, Monitoring autophagy in glioblastoma with antibody against isoform b of human microtubule-associated protein 1 light chain 3, *Autophagy* 4 (2008).
- [54] S. Jager, C. Bucci, I. Tanida, T. Ueno, E. Kominami, P. Saftig, E.L. Eskelinen, Role for Rab7 in maturation of late autophagic vacuoles, *J. Cell Sci.* 117 (2004) 4837–4848.
- [55] S. Fujii, S. Mitsunaga, M. Yamazaki, T. Hasebe, G. Ishii, M. Kojima, T. Kinoshita, T. Ueno, H. Esumi, A. Ochiai, Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome, *Cancer Sci.* 99 (2008) 1813–1819.
- [56] D.C. Rubinsztein, J.E. Gestwicki, L.O. Murphy, D.J. Klionsky, Potential therapeutic applications of autophagy, *Nat. Rev. Drug Discov.* 6 (2007) 304–312.
- [57] T. Yorimitsu, D.J. Klionsky, Eating the endoplasmic reticulum: quality control by autophagy, *Trends Cell Biol.* 17 (2007) 279–285.



Nuclear localization of SNARK; its impact on gene expression

Wataru Kuga^{a,b}, Katsuya Tsuchihara^b, Tsutomu Ogura^c, Sakyo Kanehara^{a,b},
Marie Saito^{a,b}, Atsushi Suzuki^d, Hiroyasu Esumi^{a,b,*}

^a Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba 277-8561, Japan

^b Cancer Physiology Project, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan

^c Department of Bioinformatics Sciences, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Ishikawa 920-1180, Japan

^d Division of Endocrinology and Metabolism, Department of Developmental Physiology, National Institute for Physiological Sciences, Okazaki, Aichi 444-8585, Japan

ARTICLE INFO

Article history:

Received 10 October 2008

Available online 6 November 2008

Keywords:

SNARK

AMPK-related kinase

Nuclear localization signal

Transcriptome

ABSTRACT

SNARK, a member of the AMPK-related kinases, has been involved in the cellular stress responses but its precise mechanisms remain unclear. Subcellular localization of SNARK protein was identified. Unlike cytoplasmic localizing AMPK α , SNARK was predominantly localized in the nucleus. SNARK was constitutively distributed in the nucleus even when SNARK was activated by metabolic stimuli such as AICAR and glucose-deprivation. Conserved nuclear localization signal (NLS) was identified at the N-terminal portion (⁶⁸KKAR⁷¹). Deletion and point mutation of this part resulted in the cytoplasmic translocation of mutant proteins. Furthermore, GFP fused with the SNARK fragment containing ⁶⁸KKAR⁷¹ translocated to the nucleus. A microarray analysis revealed that the nuclear localizing SNARK altered transcriptome profiles and a considerable part of these alterations were canceled by the mutation of NLS, suggesting the ability of SNARK to modulate gene expression dependent on its nuclear localization.

© 2008 Elsevier Inc. All rights reserved.

Introduction

AMPK (AMP-activated protein kinase) is a well-known cellular energy sensor. AMPK is activated in response to various metabolic stresses [1]. Once activated, AMPK phosphorylates a variety of substrates to increase catabolic pathways and decrease anabolic pathways, resulting in the maintenance of cellular energy balance [2]. AMPK is a heterotrimeric enzyme composed of an α -catalytic subunit, and β - and γ -regulatory subunits [3,4]. Two isoforms of the α -subunit have been identified. AMPK α 1 constitutively resides in the cytoplasm, whereas a portion, but not all, of the activated α 2-subunit translocates to the nucleus [5–8].

Human kinome information predicted that 12 kinases are closely related to AMPK [9,10]. SNARK (SNF1/AMPK-related kinase, also known as NUAK2) is a member of the AMPK-related kinases [11]. SNARK was originally isolated as an ultraviolet B (UVB)-induced gene in rat keratinocytes. Similar to AMPK, the kinase activity of SNARK is up-regulated by metabolic stresses [12]. Furthermore, *Snark*-deficient mice exhibited mature-onset obesity and related metabolic disorders [13]. These findings suggest the potential relevance of SNARK in cellular responses against metabolic stresses.

In this study, we attempted to identify the subcellular localization of SNARK. We found that SNARK was consistently localized in

the nucleus. We also found that SNARK was activated by AICAR as well as glucose-deprivation. We further identified the responsible nuclear localization signal (NLS) of SNARK. Finally, transcriptome profiles of wild-type and NLS mutant SNARK expressing cells were compared to identify the impact of the nuclear localization of SNARK upon the regulation of mRNA levels of potential downstream genes.

Materials and methods

Plasmid construction. The FLAG-tagged SNARK protein-expressing plasmid vector, pFLAG-SNARK has been described elsewhere [14]. pFLAG-SNARK-(2–447) was constructed by PCR amplification of the DNA sequences coding FLAG-tag and 2–447 amino acid sequences of SNARK using pFLAG-SNARK as a template and primers containing a 5' EcoRI site (SNK-D1-F) and a 3' XhoI site (SNK-D2-R). The PCR product was digested with EcoRI and XhoI and was cloned into pcDNA3.1(–) (Invitrogen). Other deletion mutant-expressing vectors were constructed as well. The PCR primers used to amplify the SNARK fragment were as follows: SNK-D1-F and SNK-D1-R for pFLAG-SNARK-(2–370), SNK-D1-F and SNK-CD(–)-R for pFLAG-SNARK-(2–169), SNK-D2-F and SNK-D2-R for pFLAG-SNARK-(78–447), SNK-CD(–)-F and SNK-D3-R for pFLAG-SNARK-(311–628), and SNK-D3-F and SNK-D3-R for pFLAG-SNARK-(390–628). pSNARK-(1–169)-GFP was constructed by PCR amplification of the 1–169 amino acid coding sequence of SNARK using primers containing a 5' SacII site (NLS-GFP-F3) and a 3' NheI

* Corresponding author. Address: Cancer Physiology Project, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan. Fax: +81 4 7134 8676.

E-mail address: hesumi@east.ncc.go.jp (H. Esumi).

site (NLS-GFP-R3). The PCR product was digested with both enzymes and was cloned into pQBI25 (MP Biomedicals, Irvine, CA). Point mutant (⁶⁸AAAR⁷¹) was also generated using two-step PCR. ⁶⁸AAAR⁷¹ was constructed using primers SNK-KKAR-F2 and SNK-KKAR-R2 as the internal primers. 3xF-EcoRI and 3xF-XbaI were used as the secondary 5'- and 3'-primers for all point mutants. The resulting amplified products were subcloned into p3xFLAG-CMV (Sigma). Mutated DNA was sequenced over their full-length to verify that they carried only the intended mutation using 3100 Sequencing Analyzer (Applied Biosystems). All the PCR primers used above are provided as Supplementary Table 1.

Cell culture. HeLa and PLC/PRF/5 cells were purchased from the American Tissue Culture Collection and were maintained in Dulbecco's modified Eagle's medium (DMEM, GIBCO) supplemented with 10% fetal bovine serum and antibiotics. Cells were cultured in a humidified chamber at 37 °C in 5% CO₂ in the air.

Transfection and establishment of stable cell lines. Cells were seeded on a 6-well plate at a density of 2×10^5 cells/well and were transfected with 4 µg of plasmid DNA using 10 µl of Lipofectamine2000 (Invitrogen) in 500 µl of Opti-MEM 1 (Invitrogen) serum-free medium and cultured for 48 h. For the selection of cells stably expressing a neomycin-resistant gene, the cells were transfected with pcDNA3.1-based plasmids and grown for 2 days. Then, 1×10^5 cells were seeded on ϕ 100 cm culture dishes and grown in the medium containing 1000 µg/mL of G418 for 14 days. The G418-containing medium was replaced every 2 days. Individual clones were picked up with incised and sterilized pieces of filter paper and were transferred to 96-well culture plates followed by consecutive transfer to larger culture plates or dishes.

Fluorescent and indirect immunofluorescent microscopy. The cells were seeded on ϕ 35 mm glass-bottomed dishes (Matsunami). For the indirect immunofluorescent microscopy, the cells were fixed in acetone-methanol (1:1) for 10 min at room temperature. The cells were blocked with 2% BSA in PBS for 1 h at room temperature. The cells were incubated with anti-FLAG M2 antibody diluted 1:500 in blocking solution for 1 h at room temperature followed by incubation with anti-mouse Alexa Fluor 488 secondary antibody (Molecular Probes) diluted 1:1000 in blocking solution for 1 h at room temperature. Nuclear DNA was counterstained with PI (Molecular Probes) in blocking solution. The cells were observed using a confocal microscope system (LSM5 PASCAL; ZEISS).

Preparation of cellular extracts. The cells were lysed in SDS lysis buffer (1% SDS, 1 mM Na₃VO₄, 10 mM Tris-HCl, pH 7.4). Nuclear and cytoplasmic extracts were prepared using the NE-PER Kit (Pierce) according to the manufacturer's instructions. The protein concentrations were determined using a BCA protein assay kit (Pierce).

Immunoblot assays. Ten micrograms of total proteins was loaded onto a 10% SDS-PAGE and electrophoresed. The separated proteins were transferred to polyvinylidene difluoride membranes (Millipore) using a semi-dry transfer. The membranes were blocked for 2 h at room temperature with 5% nonfat dry milk in PBST buffer (PBS containing 0.1% of Tween 20) and incubated with primary antibody overnight at 4 °C. The membranes were incubated with the secondary antibody conjugated to horseradish peroxidase for 1 h at room temperature. The bands of interest were detected using an ECL chemiluminescence reagent (GE Healthcare). Anti-FLAG M2 and anti-SNARK antibodies were from Sigma, anti-C23 antibody was from Santa Cruz, and anti-HSP90 antibody was from Cell Signaling.

Microarray analysis. PLC/PRF/5 cells were transfected with the empty vector p3xFLAG-CMV, the wild-type SNARK expression vector, or the ⁶⁸AAAR⁷¹ expression vector, and incubated for 24 h. Each of total RNA samples was prepared in duplicate. Total RNA was isolated using RNeasy Kit (QIAGEN). Total RNA yield was quantified by spectrophotometric analysis and quality was verified on gel electrophoresis. Total RNA (3 µg) was used in the first-strand cDNA

synthesis with T7-Oligo (dT) primer and SuperScript II reverse transcriptase (Life Technologies). The second-strand cDNA synthesis was done using One-Cycle cDNA Synthesis Kit (Affymetrix). The double-stranded cDNA was purified using sample cleanup modules and served as a template in the subsequent *in vitro* transcription reaction for complementary RNA (cRNA) amplification and biotin labeling. The biotinylated cRNA (20 µg) was fragmented and hybridized with pre-equilibrated HG-U133 Plus 2.0 Affymetrix GeneChip for 16 h at 45 °C. HG-U133 Plus 2.0 Affymetrix GeneChip contains more than 54,000 probe sets representing approximately 38,500 genes (estimated by UniGene coverage). After the hybridization cocktails were removed, the chips were washed and stained. The chips were scanned with a ChipScanner 3000 (Affymetrix) to detect hybridization signals. Scanned image output files were visually examined in order to detect major chip defects and hybridization artifacts, and then analyzed with Affymetrix GeneChip Operating software (GCOS). GCOS generates a detection *p* value from probe pair intensities and assigns a present (*P*), marginal (*M*), or absent (*A*) call to each probe set. We applied the default cut-off value of 0.04 (i.e., a *p* value under 0.04 indicates a *P* call). The normalized data were analyzed with Microsoft Excel and Gene Spring GX 7.3 software (Agilent Technologies).

Autophosphorylation and GST-SAMS phosphorylation assay. PLC/PRF/5 cells were transfected with the empty vector p3xFLAG-CMV, the wild-type SNARK expression vector, or the ⁶⁸AAAR⁷¹ expression vector, and incubated for 24 h. The cell lysates and the 6% polyethylene glycol (PEG6000) precipitates were prepared, as described previously [15]. PLC/PRF/5 cells stably expressing SNARK were treated with 1 mM AICAR or glucose-deprivation and cultured for 1 h. Cells were lysed and immunoprecipitated using anti-FLAG M2 Affinity Gel (Sigma). An autophosphorylation assay was performed with the PEG precipitates. The precipitates were incubated for 15 min at 30 °C in kinase assay buffer (15 mM Hepes, pH 7.0, 100 mM NaCl, 1% Triton X-100, 10% glycerol, 15 mM MnCl₂, 15 mM MgCl₂, and 0.3 mM DTT) with 10 µCi of [³²P]ATP [16]. The precipitates were also used for the kinase assay using SAMS peptide fused to glutathione S-transferase (GST-SAMS). GST-SAMS was prepared, as described previously [15]. The precipitates were incubated for 15 min at 30 °C in kinase assay buffer with 20 µg of GST-SAMS and 10 µCi of [³²P]ATP. These samples were subjected to 10% SDS-PAGE. Radioactivity was detected by autoradiography using FLA-7000 (Fujifilm).

Results and discussion

SNARK was distributed predominantly in the nucleus

To determine the subcellular localization of SNARK, a plasmid vector expressing FLAG-tagged SNARK were transfected into a human hepatocellular carcinoma-derived cell line PLC/PRF/5. Exogenous proteins were detected using indirect immunofluorescence. The majority of SNARK was localized in the nucleus (Fig. 1A). A similar nuclear distribution of exogenous SNARK protein was also seen in a human cancer-derived cell lines HeLa (Fig. 1A). To confirm the subcellular localization of endogenous SNARK, subcellular fractionation was carried out followed by detection of SNARK by Western blot. Endogenous SNARK was also mainly present in the nuclear fraction of both PLC/PRF/5 cells and HeLa cells (Fig. 1B). C23 and HSP90 were used as markers of the nuclear and cytosolic fractions, respectively.

SNARK was constitutively distributed in the nucleus

To ask whether the subcellular localization of SNARK is altered by various stimuli, SNARK overexpressing cells were treated by




Fig. 1. Subcellular localization of SNARK. (a) Confocal microscopy of PLC/PRF/5 cells transiently expressing FLAG-SNARK. Green, FLAG-tagged proteins immunostained with anti-FLAG M2 antibody. Red, Nuclei visualized by counter-staining DNA with PI. Original magnification, 630 \times . (b) Immunoblot of the cytosolic and nuclear fractions from PLC/PRF/5 cells. Equal amounts (10 μ g) of nuclear (N), cytosolic (C), and total (T) extracts from PLC/PRF/5 were analyzed by 10% SDS-PAGE. C23 and HSP90 were used as markers of the nuclear and cytosolic fractions, respectively.

1 mM AICAR, a representative AMPK activator, and glucose-deprivation which is known to activate SNARK [12]. As expected, over-expressed SNARK showed enhanced activity against SAMS peptides (Fig. 2A). Subcellular fractionation and immunofluorescent detection of SNARK demonstrated that most of SNARK stay in the nucleus under these stimuli (Fig. 2B and C).

Identification of a functional nuclear localization signal in SNARK

To explore the mechanism of the preferential nuclear localization of SNARK, potential NLS motifs were searched among the ami-

no acid sequences of SNARK. The minimum requirement for a monopartite NLS is Lys-Lys/Arg-X-Lys/Arg (K-K/R-X-K/R) [17,18]. Three candidate sequences, 68 KKAR 71 , 375 KKS 378 , and 450 KKPR 453 were predicted based on the amino acid sequences of human SNARK. To identify the functional NLS in SNARK, a series of constructs expressing deletion mutants with FLAG-tag were prepared (Supplementary Figure 1a). The expression of each mutant was confirmed using immunoblotting (Supplementary Figure 1b). The subcellular localization of the series of transiently expressed mutant proteins was determined using immunofluorescence. FLAG-SNARK-(2–447), FLAG-SNARK-(2–370), and FLAG-SNARK-(2–169), which contain 68 KKAR 71 , exhibited apparent nuclear localization, whereas FLAG-SNARK-(78–447), FLAG-SNARK-(311–628), and FLAG-SNARK-(390–628), each of which lacked 68 KKAR 71 , were localized predominantly in the cytoplasm (Fig. 3). These results suggest that 68 KKAR 71 functions as a NLS motif in SNARK. On the other hand, the presence or the absence of 375 KKS 378 and 450 KKPR 453 did not affect the localization of mutant proteins.

To determine whether 68 KKAR 71 functions as a NLS, site-directed mutagenesis of this motif was performed. The first two core lysine residues of 68 KKAR 71 were altered to alanine (68 AAAR 71) (Supplementary Figure 2a). The expression of this mutant was confirmed by Immunoblotting (Supplementary Figure 2b). The resulting mutant protein exhibited a significantly altered localization. The 68 AAAR 71 -mutant was mainly localized in the cytoplasm and small part of proteins remained in the nucleus (Fig. 4A). The distributions of wild-type and 68 AAAR 71 -mutant SNARK proteins were evaluated in at least 300 transfected cells. Wild-type SNARK was dominantly localized in the nucleus in about 90% of the cells, whereas 68 AAAR 71 -mutant was localized mainly in the cytoplasm and partially in the nucleus (Fig. 4B). Thus, 68 KKAR 71 was necessary for the localization of SNARK in the nucleus. Since the kinase activity of 68 AAAR 71 -mutant was as high as that of wild-type SNARK, kinase activity of SNARK was not indispensable for the nuclear localization (Fig. 4C).

To further confirm the NLS function, the N-terminal 169 amino acid-length fragment of SNARK containing 68 KKAR 71 was fused to GFP (Supplementary Figure 2c). The expression of this mutant was confirmed by Immunoblotting (Supplementary Figure 2d). SNARK-(1–169)-GFP was localized predominantly in the nucleus,




Fig. 2. The association between the activation and localization in SNARK. (a) *In vitro* kinase assay of SNARK stimulated by AICAR and glucose-deprivation. The immunoprecipitants of FLAG-SNARK were prepared from lysates of SNARK expressing PLC/PRF/5 cells treated with 1 mM AICAR or glucose-deprivation for an hour and used to perform a kinase assay with GST-SAMS as substrate. Upper panel indicates *in vitro* kinase assay, and lower panel indicates anti-FLAG immunoblot, respectively. (b) Immunoblot of the cytosolic and nuclear fractions from PLC/PRF/5 cells. Equal amounts (10 μ g) of nuclear (N), cytosolic (C), and total (T) extracts from PLC/PRF/5 treated with indicated stimuli were analyzed by 10% SDS-PAGE. C23 and HSP90 were used as markers of the nuclear and cytosolic fractions, respectively. (c) Confocal microscopy of cells expressing FLAG-SNARK. PLC/PRF/5 cells expressing FLAG-SNARK were treated with indicated stimuli. Green, FLAG-SNARK immunostained with anti-FLAG M2 antibody. Red, nuclei visualized by counter-staining DNA with PI. Original magnification, 630 \times .